Clinical Trial

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

Name: A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors — clinical trial record (NCT07160725)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors

Protocol Amendment History 2 changes

notable Enrollment increased: 315 -> 540 participants 2026-07-25

minor Trial arms changed: 4 -> 8 2026-07-25

Trial Details

NCT Number	NCT07160725
Lead Sponsor	Bristol-Myers Squibb
Conditions	Solid Tumours
Enrollment	540 participants
Start Date	2025-10-15
Primary Completion	2028-07-31 (estimated)
Study Completion	2028-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-11